Key facts
- It has raised $11.9M across 3 recorded rounds; the latest was Early Stage VC ($6.0M) in Feb 2025.
- Notable investors include CARB-X, Standish Spring Investments, LabCentral, Standish Capital.
- Lytica Therapeutics has filed 3 Form Ds with the SEC since 2024, most recently Apr 2025 ($6.0M sold to 17 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Lytica Therapeutics
Funding rounds
3 roundsAbout Lytica Therapeutics
Operator of a biotechnology company intended to develop novel peptide conjugates for next-generation Antibody-Drug Conjugates (ADCs). The company taps into a natural reserve of compounds known as antimicrobial peptides (AMPs) to develop therapeutic keys that tackle the rising problem of antibiotic resistance using their proprietary technology, they have created a novel class of antibiotics with potent activity and a reduced propensity for bacterial resistance, helping patients by providing successful therapy.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2019
- Employees
- 10
- Website
- lyticatherapeutics.com/
- Ownership
- Privately Held (backing)
Lytica Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Lytica Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Lytica Therapeutics in its N-PORT filings yet. We sweep new filings monthly.